Predicting Response to Cancer Therapies
Trovagene is developing oncology therapeutics for improved cancer care. We are optimizing drug development by leveraging our proprietary Precision Cancer Medicine®, or PCM, technology in tumor genomics.
Our technology enables us to measure ctDNA in urine and blood. This means the power to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.
Beginning with PCM-075, we can first target the unmet medical needs of patients with Acute Myeloid Leukemia (AML), an aggressive cancer of the blood and bone marrow with approximately 20,000 new cases in the U.S each year.
PCM-075 has demonstrated potential synergy in combination with numerous chemotherapeutics and targeted therapies. We believe this enables us to enhance current and future standard-of-care and presents significant market opportunities.
Our Lead Therapeutic Candidate
PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. It is an oral, highly selective competitive inhibitor of the PLK1 enzyme which is commonly overexpressed in many hematologic and solid tumor cancers.
These attributes combined with its potential synergy with numerous chemotherapeutic and targeted therapies make PCM-075 a highly attractive drug candidate.
Developing PCM-075 to Address Clinical Therapeutic Needs
High PLK1 expression is associated with the most aggressive forms of hematologic and solid tumor cancers. We believe that due to PCM-075’s high selectivity to PLK1, we have the opportunity expand the therapeutic benefit of PCM-075 beyond Acute Myeloid Leukemia to other hematologic and solid tumor cancers, including Non-Hodgkin Lymphoma and metastatic Castration-Resistant Prostate Cancer.
Our development of PCM-075, and the potential synergistic effect when combined with numerous chemotherapeutics and targeted therapies may enhance the efficacy of current and future standard-of-care therapies which present significant market opportunities.